Alzheimer Disease

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Check out the pipeline updates from January!

The lates update in lecanemab’s journey: the FDA has accepted the BLA for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing.

The FDA grants Breakthrough Device Designation to Spear Bio’s pTau 217 blood test for Alzheimer disease.

The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer disease.

Do lifestyle interventions really work in Alzheimer disease and what are the underlying mechanisms? Learn more in this ACNP 2024 Annual Meeting session!

In this CME article, learn more about the efficacy and tolerability of brexpiprazole for the treatment of agitation among individuals with Alzheimer disease dementia.

As a treatment, low-dose lithium can act like a bridge between medications and integrative approaches, supporting well-being with reduced adverse effects.

A traumatic brain injury sustained earlier in adult life is likely to interact with normal aging processes. Learn more here.

The behavioral and psychological symptoms of dementia contribute significantly to the greater rates morbidity and mortality among those with dementia.

Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.

Review the multiple uses of metformin.

Here are highlights from the week in Psychiatric Times.

The FDA Advisory Committee recommended donanemab, which could lead to its approval later this year.

Here are highlights from the week in Psychiatric Times.

Eisai and Biogen announced they have initiated a rolling submission for subcutaneous Leqembi for Alzheimer disease.

This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

Have you checked out the latest Translating Research Into Practice column? Let us know!

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

Alzheimer disease treatment donanemab will be delayed as the FDA plans to convene a committee meeting to evaluate the phase 3 Trailblazer-Alz 2 trial.

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

AVP-786, a drug to treat agitation associated with Alzheimer disease dementia, failed to meet the primary efficacy endpoint in a phase 3 clinical trial.

Available evidence from preclinical studies indicates that semaglutide shows promise for treating Alzheimer disease and Parkinson disease.

From pain and suicidality in patients with depression to digital mental health interventions for adolescents with eating disorders, here are highlights from the week in Psychiatric Times.

A new study correlates reduced serotonin transporter and increased amyloid-ß deposition with cognitive deficits in mild cognitive impairment, suggesting a role for serotonergics in early Alzheimer disease.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

Biogen announced its decision to discontinue all development and sales of aducanumab (Aduhelm) for Alzheimer disease. Is this surprising?